AKR1B1 and malignant colon neoplasm: With the help of these powerful aldo-keto reductase inhibitors, it may be possible to synthesize potential new pharmaceuticals that cure colon cancers associated with aberrant expression of the AKR1B1 or AKR1B10 protein.